OBJECTIVE: With distinct optical attributes (e.g., robust photostability, restricted emission spectra, tunable broad excitation, and high quantum output), fluorescent quantum dots (QDs) have been feasibly functionalized with manageable interfaces and considerably utilized as a new class of optical probe in biological investigations.
METHODS: In this review article, we structured the current advancements in the preparation methods and attributes of QDs. Furthermore, we extend an overview of the outstanding potential of QDs for biomedical research and radical approaches to drug delivery.
CONCLUSION: Notably, the applications of QDs as smart next-generation nanosystems for neuroscience and pharmacokinetic studies have been explained. Moreover, recent interests in the potential toxicity of QDs are also apprised, ranging from cell investigations to animal studies.
METHODS: We screened the in-house built fluorescent library compounds that specifically bind human iPS cells. After tertiary screening, the selected probe was analyzed for its ability to detect reprogramming cells in the time-dependent manner using high-content imaging analysis. The probe was compared with conventional dyes in different reprogramming methods, cell types, and cell culture conditions. Cell sorting was performed with the fluorescent probe to analyze the early reprogramming cells for their pluripotent characteristics and genome-wide gene expression signatures by RNA-seq. Finally, the candidate reprogramming factor identified was investigated for its ability to modulate reprogramming efficiency.
RESULTS: We identified a novel BODIPY-derived fluorescent probe, BDL-E5, which detects live human iPS cells at the early reprogramming stage. BDL-E5 can recognize authentic reprogramming cells around 7 days before iPS colonies are formed and stained positive with conventional pluripotent markers. Cell sorting of reprogrammed cells with BDL-E5 allowed generation of an increased number and higher quality of iPS cells. RNA sequencing analysis of BDL-E5-positive versus negative cells revealed early reprogramming patterns of gene expression, which notably included CREB1. Reprogramming efficiency was significantly increased by overexpression of CREB1 and decreased by knockdown of CREB1.
CONCLUSION: Collectively, BDL-E5 offers a valuable tool for delineating the early reprogramming pathway and clinically applicable commercial production of human iPS cells.